Lost in translation: Neuropsychiatric drug development

Science Translational Medicine

Volumn 2, Issue 61, 2010, Pages

  Becker, Robert E ^a,b   Greig, Nigel H ^b  

^a Aristea Translational Medicine Corp   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE; NEUROLEPTIC AGENT; PLACEBO; TARENFLURBIL; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS;

ALZHEIMER DISEASE; ANALYTICAL ERROR; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; ENVIRONMENTAL FACTOR; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEREDITY; HUMAN; INTERVENTION STUDY; MENTAL DISEASE; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PSYCHOSIS; PUBLICATION; SCHIZOPHRENIA; VALIDITY; ANIMAL; DISEASE MODEL; DRUG DESIGN; METHODOLOGY; NEUROPSYCHIATRY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALS; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; GUIDELINES AS TOPIC; HUMANS; MENTAL DISORDERS; NEUROPSYCHIATRY; TRANSLATIONAL RESEARCH;

EID: 78650185148     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000446     Document Type: Article

References (65)

1. D. L. Sackett, S. E. Strauss, W. S. Richardson, W. Rosenberg, R. B. Haynes, Evidence-Based Medicine: How to Practice and Teach EBM (Churchill Livingstone, New York, 2000).
2. A. Markou, C. Chiamulera, M. A. Geyer, M. Tricklebank, T. Steckler, Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology 34, 74-89 (2009).
3. N. Engelhardt, A. D. Feiger, K. O. Cogger, D. Sikich, D. J. DeBrota, J. D. Lipsitz, K. A. Kobak, K. R. Evans, W. Z. Potter, Rating the raters: Assessing the quality of Hamilton Rating Scale for Depression clinical interviews in two industry-sponsored clinical drug trials. J. Clin. Psychopharmacol. 26, 71-74 (2006).
4. K. O. Cogger, Rating rater improvement: A method for estimating increased effect size and reduction of clinical trial costs. J. Clin. Psychopharmacol. 27, 418-420 (2007).
5. R. E. Becker, S. Markwell, Problems arising from generalizing of treatment efficacy from clinical trials in Alzheimer's disease. Clin. Drug Invest. 19, 33-41 (2000).
6. A. W. Chan, A. Hróbjartsson, K. J. Jørgensen, P. C. Gøtzsche, D. G. Altman, Discrepancies in sample size calculations and data analyses reported in randomised trials: Comparison of publications with protocols. BMJ 337, a2299 (2008).
7. I. Boutron, S. Dutton, P. Ravaud, D. G. Altman, Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303, 2058-2064 (2010).
8. E. H. Turner, A. M. Matthews, E. Linardatos, R. A. Tell, R. Rosenthal, Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358, 252-260 (2008).
9. M. N. Pangalos, L. E. Schechter, O. Hurko, Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6, 521-532 (2007).
10. R. E. Becker, N. H. Greig, Alzheimer's disease drug development in 2008 and beyond: Problems and opportunities. Curr. Alzheimer Res. 5, 346-357 (2008).
11. I. Kola, J. Landis, Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
12. J. Reason, Human Error (Cambridge University Press, Cambridge, 2001).
13. B. N. Swanson, Delivery of high-quality biomarker assays. Dis. Markers 18, 47-56 (2002).
14. K. S. Kendler, Explanatory models for psychiatric illness. Am. J. Psychiatry 165, 695-702 (2008).
15. K. S. Kendler, Toward a philosophical structure for psychiatry. Am. J. Psychiatry 162, 433-440 (2005).
16. M. P. McDonald, J. B. Overmier, Present imperfect: A critical review of animal models of the mnemonic impairments in Alzheimer's disease. Neurosci. Biobehav. Rev. 22, 99-120 (1998).
17. K. Yamada, T. Nabeshima, Animal models of Alzheimer's disease and evaluation of antidementia drugs. Pharmacol. Ther. 88, 93-113 (2000).
18. J. Götz, J. R. Streffer, D. David, A. Schild, F. Hoerndli, L. Pennanen, P. Kurosinski, F. J. Chen, Transgenic animal models of Alzheimer's disease and related disorders: Histopathology, behavior and therapy. Mol. Psychiatry 9, 664-683 (2004).
19. E. Fuchs, G. Flïugge, Experimental animal models for the simulation of depression and anxiety. Dialogues Clin. Neurosci. 8, 323-333 (2006).
20. R. E. Becker, N. H. Greig, Alzheimer's disease drug development: Old problems require new priorities. CNS Neurol. Disord. Drug Targets 7, 499-511 (2008).
21. J. E. Barrett, J. M. Witkin, Application of behavioral techniques to central nervous system (CNS) drug discovery and development, in Behavioral Pharmacology, A. Bespalov, E. Zvartau, P. Beardsley, J. Katz, Eds. (PITER Publishing, St. Petersburg, Russia, 2009), pp. 430-455.
22. P. Willner, P. J. Mitchell, The validity of animal models of predisposition to depression. Behav. Pharmacol. 13, 169-188 (2002).
23. I. Chalmers, Underreporting research is scientific misconduct. JAMA 263, 1405-1408 (1990).
24. S. J. Mathew, D. S. Charney, Publication bias and the efficacy of antidepressants. Am. J. Psychiatry 166, 140-145 (2009).
25. R. E. Becker, N. H. Greig, Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr. Alzheimer Res. 7, 642-651 (2010).
26. M. O. Baerlocher, J. O'Brien, M. Newton, T. Gautam, J. Noble, Data integrity, reliability and fraud in medical research. Eur. J. Intern. Med. 21, 40-45 (2010).
27. J. Worrall, Why there's no cause to randomize. Br. J. Philos. Sci. 58, 451-488 (2007).
28. M. A. Demitrack, D. Faries, J. M. Herrera, D. DeBrota, W. Z. Potter, The problem of measurement error in multisite clinical trials. Psychopharmacol. Bull. 34, 19-24 (1998).
29. K. A. Kobak, J. D. Lipsitz, J. B. Williams, N. Engelhardt, K. M. Bellew, A new approach to rater training and certification in a multicenter clinical trial. J. Clin. Psychopharmacol. 25, 407-412 (2005).
30. J. Butcher, The hunt for drugs to modify Alzheimer's disease. Lancet Neurol. 6, 1038-1039 (2007).
31. R. E. Becker, Lessons from Darwin: 21st century designs for clinical trials. Curr. Alzheimer Res. 4, 458-467 (2007).
32. G. P. Samsa, D. B. Matchar, Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 32, 669-674 (2001).
33. D. Moher, A. Jones, L. Lepage; CONSORT Group (Consolidated Standards for Reporting of Trials), Use of the CONSORT statement and quality of reports of randomized trials: A comparative before-and-after evaluation. JAMA 285, 1992-1995 (2001).
34. C. De Angelis, J. M. Drazen, F. A. Frizelle, C. Haug, J. Hoey, R. Horton, S. Kotzin, C. Laine, A. Marusic, A. J. Overbeke, T. V. Schroeder, H. C. Sox, M. B. Van Der Weyden; International Committee of Medical Journal Editors, Clinical trial registration: A statement from the International Committee of Medical Journal Editors. N. Engl. J. Med. 351, 1250-1251 (2004).
35. J. Moncrieff, The antidepressant debate. Br. J. Psychiatry 180, 193-194 (2002).
36. R. E. Becker, N. H. Greig, E. Giacobini, Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J. Alzheimers Dis. 15, 303-325 (2008).
37. J. Cohen, Things I have learned (so far). Am. Psychol. 45, 1304-1312 (1990).
38. R. E. Becker, N. H. Greig, Neuropsychiatric clinical trials: Should they accommodate real-world practices or set standards for clinical practices? J. Clin. Psychopharmacol. 29, 56-64 (2009).
39. R. B. Braithwaite, Scientific Explanation (Thoemmes Press, Bristol, UK, 1994), pp. 270-271.
40. K. A. Kobak, D. J. DeBrota, N. Engelhardt, J. B. W. Williams, Site vs. centralized raters in a clinical depression trial, paper presented at the 46th Annual Meeting of the National Institute of Mental Health, New Clinical Drug Evaluation Unit, Boca Raton, FL, 2006.
41. J. A. Bridge, B. Birmaher, S. Iyengar, R. P. Barbe, D. A. Brent, Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am. J. Psychiatry 166, 42-49 (2009).
42. G. J. Emslie, Understanding placebo response in pediatric depression trials. Am. J. Psychiatry 166, 1-3 (2009).
43. J. L. Eriksen, S. A. Sagi, T. E. Smith, S. Weggen, P.Das, D. C.McLendon, V. V. Ozols, K. W. Jessing, K. H. Zavitz, E. H. Koo, T. E. Golde, NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. 112, 440-449 (2003).
44. S. Weggen, J. L. Eriksen, P. Das, S. A. Sagi, R. Wang, C. U. Pietrzik, K. A. Findlay, T. E. Smith, M. P. Murphy, T. Bulter, D. E. Kang, N. Marquez-Sterling, T. E. Golde, E. H. Koo, A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
45. T. A. Lan, G. J. Fici, K. M. Merchant, Lack of specific amyloid-β(1-42) suppression by non-steroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther. 312, 399-406 (2005).
46. G. K. Wilcock, S. E. Black, S. B. Hendrix, K. H. Zavitz, E. A. Swabb, M. A. Laughlin; Tarenflurbil Phase II Study investigators, Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomised phase II trial. Lancet Neurol. 7, 483-493 (2008).
47. R. E. Becker, L. K. Unni, N. H. Greig, Resurrecting clinical pharmacology as a context for Alzheimer disease drug development. Curr. Alzheimer Res. 6, 79-81 (2009).
48. D. R. Galasko, N. Graff-Radford, S. May, S. Hendrix, B. A. Cottrell, S. A. Sagi, G. Mather, M. Laughlin, K. H. Zavitz, E. Swabb, T. E. Golde, M. P. Murphy, E. H. Koo, Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis. Assoc. Disord. 21, 292-299 (2007).
49. J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, J. Severe, J. K. Hsiao; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
50. M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. Keefe, J. K. Hsiao, J. A. Lieberman, What CATIE found: Results from the schizophrenia trial. Psychiatr. Serv. 59, 500-506 (2008).
51. T. S. Stroup, J. A. Lieberman, J. P. McEvoy, S. M. Davis, M. S. Swartz, R. S. Keefe, A. L. Miller, R. A. Rosenheck, J. K. Hsiao; CATIE Investigators, Results of phase 3 of the CATIE schizophrenia trial. Schizophr. Res. 107, 1-12 (2009).
52. J. A. Lieberman, What the CATIE study means for clinical practice. Psychiatr. Serv. 57, 1075 (2006).
53. E. R. Heerdink, J. J. Stolker, W. E. Meijer, G. W. Hugenholtz, A. C. Egberts, Need for medicine-based evidence in pharmacotherapy. Br. J. Psychiatry 184, 452 (2004).
54. R. A. Rosenheck, S. Davis, N. Covell, S. Essock, M. Swartz, S. Stroup, J. McEvoy, J. Lieberman, Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr. Res. 107, 22-29 (2009).
55. R. Rosenheck, D. Leslie, R. Keefe, J. McEvoy, M. Swartz, D. Perkins, S. Stroup, J. K. Hsiao, J. Lieberman; CATIE Study Investigators Group, Barriers to employment for people with schizophrenia. Am. J. Psychiatry 163, 411-417 (2006).
56. W. A. Anthony, Psychiatric rehabilitation: A key to prevention. Psychiatr. Serv. 60, 3 (2009).
57. R. E. Becker, The challenge of rehabilitation, in Strategic Intervention in Schizophrenia: Current Development in Treatment, R. Cancro, N. Fox, L. E. Shapiro, Eds. (Behavioral Publications, New York, 1974), pp. 261-278.
58. R. E. Becker, An evaluation of a rehabilitation program for chronically hospitalized psychiatric patients. Soc. Psychiatry Psychiatr. Epidemiol. 2, 32-38 (1967).
59. L. I. Stein, M. A. Test, A. J. Marx, Alternative to the hospital: A controlled study. Am. J. Psychiatry 132, 517-522 (1975).
60. R. E. Becker, N. Meisler, G. Stormer, M. J. Brondino, Employment outcomes for clients with severe mental illness in a PACT model replication. Program for Assertive Community Treatment. Psychiatr. Serv. 50, 104-106 (1999).
61. M. S. Swartz, D. O. Perkins, T. S. Stroup, S. M. Davis, G. Capuano, R. A. Rosenheck, F. Reimherr, M. F. McGee, R. S. Keefe, J. P. McEvoy, J. K. Hsiao, J. A. Lieberman; CATIE Investigators, Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE study. Am. J. Psychiatry 164, 428-436 (2007).
62. W. T. Carpenter Jr., Targeting schizophrenia research to patient outcomes. Am. J. Psychiatry 163, 353-355 (2006).
63. R. E. Becker, Psychiatry: The importance of understanding persons while treating diagnoses. Sci. Culture 17, 317-334 (2008).
64. R. E. Becker, Modifying clinical trial designs to test treatments for clinical significance in individual patients. Clin. Drug Invest. 21, 727-733 (2001).
65. L. J. Thal, K. Kantarci, E. M. Reiman, W. E. Klunk, M. W. Weiner, H. Zetterberg, D. Galasko, D. Praticò, S. Griffin, D. Schenk, E. Siemers, The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, 6-15 (2006).